"I look forward to working with CoLucid to help identify key business targets and to set the future direction of CoLucid's product development and partnering strategies," said Hogan. "I am very excited about the market and partnering potential for the company's pipeline of innovative CNS product candidates."
CoLucid Pharmaceuticals recently announced positive results from its Phase II clinical study of its lead compound, COL-144, in the treatment of acute migraine. Findings from the study demonstrated that COL-144 is effective in relieving migraine headaches and is well tolerated.
COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. In addition to COL-144, CoLucid's pipeline includes a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. COL-204, the lead compound in the conjugated stigmine program, is expected to enter clinical development in 2009 for wake promotion.
About CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures
to advance innovative drug candidates with the potential to provide safe
and effective treatment for central nervous system (CNS) disorders. The
company's pipeline includes COL-144, a novel treatment for migraine
headache, and a conjugated stigmine platform that has generated a series of
preclinical candidates for t
|SOURCE CoLucid Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved